Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin-A Systemic Literature Review and Network Meta-analysis

被引：0
|
作者：
Home, Philip
Lauand, Felipe
Djaballah, Khier
Bourhis, Francois
Li, Xuan
Hafidh, Khadija
Mehta, Roopa
Faraoun, Khadra
Anaforoglu, Inan
Pourrahmat, Mir-Masoud
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1880-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1880-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies
    Home, Philip
    Lauand, Felipe
    Djaballah, Khier
    Li, Xuan-Tony
    Hafidh, Khadija
    Mehta, Roopa
    Faraoun, Khadra
    Anaforoglu, Inan
    Serafini, Paul
    Pourrahmat, Mir-Masoud
    DIABETES OBESITY & METABOLISM, 2025,
  • [2] COMPARATIVE EFFICACY AND SAFETY OF LIXISENATIDE AND INSULIN REGIMENS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Men, P.
    Qu, S.
    Luo, W.
    Liu, Y.
    Li, C.
    Zhai, S.
    VALUE IN HEALTH, 2018, 21 : S35 - S35
  • [3] Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
    Edina, Brenda C.
    Tandaju, Jeremy R.
    Wiyono, Lowilius
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [4] Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials
    Li, Jingxin
    Wang, Xiaomin
    Wu, Jingcheng
    Geng, Dandan
    Li, Fan
    Liu, Yang
    Shen, Yanhong
    ENDOCRINE, 2025,
  • [5] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    DIABETES, 2017, 66 : A252 - A252
  • [6] Efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drug(s): the SoliD randomised controlled trial
    Li, Y.
    Gu, W.
    Chen, L.
    Kuang, H.
    Du, J.
    Alvarez, A.
    Lauand, F.
    Souhami, E.
    Zhang, J.
    Xu, W.
    Du, Q.
    Mu, Y.
    Liu, M.
    DIABETOLOGIA, 2024, 67 : S378 - S378
  • [7] Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis
    Men, Peng
    Qu, Shuli
    Luo, Wenting
    Li, Chaoyun
    Zhai, Suodi
    DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 107 - 115
  • [8] SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS
    Jammah, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A185 - A186
  • [9] Efficacy and safety of iGlarLixi vs insulin glargine 100 U/ml in Chinese people with type 2 diabetes (T2D) inadequately controlled on basal insulin (BI): LixiLan-L-China trial
    Guo, X.
    Zhang, J.
    Dong, X.
    Lu, Y.
    Pang, W.
    Gu, S.
    Ping, L.
    Nian, G.
    Niemoeller, E.
    Souhami, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 270 - 270
  • [10] Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)-The SoliD Randomized Controlled Trial
    Liu, Ming
    Gu, Weijun
    Chen, Li
    Li, Yanbing
    Kuang, Hongyu
    Du, Jianling
    Alvarez, Agustina
    Lauand, Felipe, Sr.
    Souhami, Elisabeth
    Zhang, Jiewen
    Xu, Weiya
    Du, Qin
    Mu, Yiming
    DIABETES, 2024, 73
12345